MiMedx Group proposes merging Sanara MedTech into a wholly owned subsidiary, giving each eligible Sanara share $33.00 in cash and 0.4735 MiMedx shares. The structure matters because Sanara shareholders must approve it, and the stock portion’s Market Value will fluctuate with MiMedx shares before closing.

Key Highlights

  • MiMedx and Sanara entered a Merger agreement on July 29, 2026.
  • Each eligible Sanara share would receive $33.00 in cash and 0.4735 MiMedx shares.
  • Sanara shareholders will vote on the merger at a virtual special meeting on September 30, 2026.

MiMedx Group, Inc. (NASDAQ: MDXG) entered an agreement to merge with Sanara MedTech, under which each eligible Sanara share would receive $33.00 in cash and 0.4735 MiMedx shares.

September 30 Vote Will Decide Proposed Merger

The merger agreement was signed on July 29, 2026, among MiMedx, Mustang Merger Sub and Sanara. Sanara would survive the transaction as a wholly owned MiMedx subsidiary. Sanara’s special meeting will be held virtually on September 30, 2026, with shareholders voting on the merger, an advisory compensation proposal and a possible adjournment. MiMedx and Sanara cannot complete the transaction without approval of the merger proposal. Sanara’s board unanimously approved the agreement and recommended that shareholders adopt it.

Implied Consideration Reaches $35.14

MiMedx common stock closed at $4.36 and Sanara common stock at $26.64 on July 28, 2026, producing implied merger consideration of $35.06 per Sanara share. On September 1, MiMedx closed at $4.52 and Sanara at $34.79, while the implied consideration was $35.14. The stock component’s market value will fluctuate with MiMedx’s share price.